# ALCAMENA STEM CELL THERAPEUTICS, LLC: FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | ALCAMENA STEM CELL THERAPEUTICS, LLC |
| Location | Baltimore, MD |
| Project | FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain |
| Project number | 5R44NS145934-02 |
| Mechanism | R44 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $1,500,000 |
| Awarded | 2026-09-04 |
| Project period | 2025-08-07 to 2027-07-31 |
| UEI | J6DAAQH7AQL8 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11387927). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.